uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of uniQure (NASDAQ:QURE) from a sell rating to a hold rating in a report issued on Saturday,Wall Street Zen reports.

QURE has been the topic of several other research reports. Stifel Nicolaus set a $71.00 price objective on shares of uniQure in a report on Wednesday, November 4th. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, September 29th. The Goldman Sachs Group reduced their target price on uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a report on Wednesday, September 30th. Wolfe Research upgraded shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research report on Wednesday, July 29th. Finally, UBS Group started coverage on uniQure in a research report on Thursday, October 15th. They issued a “buy” rating and a $48.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $56.83.

uniQure Stock Performance

uniQure stock opened at $22.79 on Friday. The company has a current ratio of 11.52, a quick ratio of 10.01 and a debt-to-equity ratio of 0.17. The business’s 50-day moving average price is $31.34 and its two-hundred day moving average price is $29.69. uniQure has a 12-month low of $8.73 and a 12-month high of $51.72.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04. The company had revenue of $5.20 million for the quarter, compared to the consensus estimate of $6.17 million. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. On average, sell-side analysts predict that uniQure will post -3.84 earnings per share for the current year.

Institutional Trading of uniQure

Several institutional investors have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP acquired a new stake in uniQure during the 2nd quarter valued at approximately $15,254. IFP Advisors Inc increased its stake in shares of uniQure by 18.0% in the third quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 500 shares during the period. Arizona State Retirement System increased its stake in shares of uniQure by 17.7% in the second quarter. Arizona State Retirement System now owns 12,940 shares of the biotechnology company’s stock worth $596,000 after acquiring an additional 1,942 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of uniQure during the third quarter worth $86,000. Finally, Rangeley Capital LLC lifted its position in uniQure by 52.9% during the first quarter. Rangeley Capital LLC now owns 13,000 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 4,500 shares during the period. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands.

Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.